Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Essential and Non-essential Amino Acid Ingredients to Account for Over 70% Phenylketonuria Treatment: Persistence Market Research


News provided by

Persistence Market Research Pvt. Ltd.

25 Feb, 2021, 12:00 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Phenylketonuria (PKU) is an inherited disorder caused by excess of phenylalanine in the blood, which can lead to severe intellectual disabilities. There is no cure for phenylketonuria as yet, and dietary management is the only option to maintain the phenylalanine level in the body. Untreated infants with PKU tend to have unusually light eye, skin, and hair colour due to excess of phenylalanine levels interfering with melanin. Neurological symptoms such as seizures, abnormal muscle movement, tremors, or involuntary movement are some of the symptoms mainly observed in such patients.

Continue Reading
This image opens in the lightbox
PMR Logo

Rising prevalence of phenylketonuria among newborns and surging demand for novel formulations to treat the disease have led to increased opportunities for market players. Stakeholders are investing more in research & development for novel treatment solutions within the nutraceutical industry.

According to the latest report published by Persistence Market Research, the global phenylketonuria treatment market for protein ingredients was valued at US$ 325.9 Mn in 2019, and is predicted to witness an impressive CAGR of over 6% during the forecast period (2020–2030). Similarly, the market for finished products was valued at US$ 565.8 Mn in 2019, and is predicted to witness an impressive CAGR of around 7% through 2030.

Key Takeaways from Phenylketonuria Treatment Market Study       

  • For Protein Ingredients
    • Essential and non-essential amino acid ingredients are expected to contribute more than 1/3 of the revenue share in the market.
    • Powder blend form is expected to gain traction in phenylketonuria treatment, accounting for more than 90% share throughout the forecast years.
    • By targeted customer, consumer healthcare companies hold the highest share of more than 80% in this space.
    • By sales channel, industry sales of protein ingredients are dominating the market.
    • North America holds the highest share in the global phenylketonuria treatment market, owing to the presence of big market players and growing research & development efforts in the region.
    • Key players are focused on expanding their product portfolios and expansion at regional levels through collaborations and acquisitions.
    • The market in the U.S. is projected to be the fastest-growing at a CAGR above 6.5% through 2030. The U.S. holds a big portion of the market revenue and accounts for more than 90% in North America.
  • For Finish Products
    • Essential and non-essential amino acids are expected to contribute more than 1/3 of the revenue share in the market.
    • The powder & granules form is expected to dominate phenylketonuria treatment, accounting for a share of more than 50% through 2030.
    • By targeted customer, adults account for the highest market share of more than 50%.
    • By sales channel, hypermarkets and supermarkets will hold the highest share throughout the forecast period.
    • North America holds more than 40% of the global phenylketonuria treatment market share.
    • Key market players are focusing on expansion of their product portfolios by highly investing in the research & development sector, and are generating high revenue through collaborations and acquisitions.
    • The market in the U.S. is projected to be the fastest-growing, and will expand at a CAGR close to 6% through 2030. The U.S. holds a big portion of the market revenue, and accounts for more than 90% share in North America.

Get the Sample PDF of the Report:  https://www.persistencemarketresearch.com/samples/14410

"Increasing prevalence of PKU and rising adoption of PKU diets will upswing the global phenylketonuria treatment market over the coming years," says an analyst of Persistence Market Research.

Get Full Access of Report: https://www.persistencemarketresearch.com/checkout/14410

Collaborations & Acquisitions Key Strategies amongst Market Players

Prominent players in the phenylketonuria treatment market are firming their product ranges through acquisitions and reaching out to emerging markets. Increasing investments and manufacturing capacity expansion are expected to favour growth of the global market over the forecast period.

  • For instance, Mead Johnson Nutrition Company was acquired by the Reckitt Benckiser Group plc (RB). Mead Johnson is now a division of RB, adding its globally-recognized brands, including Phenyl-Free® 1, an iron-fortified PKU infant formula and medical food powder for infants and young children with documented phenylketonuria.
  • Additionally, Abbott Laboratories collaborated with Syngene to inaugurate its first nutrition research & development centre in India.

Various players in the phenylketonuria treatment market are focusing on research & development, product launches, and advanced solutions to strengthen and expand their product portfolios.

  • For instance, Vitaflo USA introduced PKU Sphere™, a powdered, low phenylalanine medical food used in the dietary management of phenylketonuria. The medical food formula is a Glycomacropeptide (GMP)-based medical food containing a balanced mix of GMP and amino acids.
  • Ajinomoto Co., Inc. introduced a new product line, Glytactin BUILD 20/20™ and Glytactin RTD Lite, new PKU formulas featuring the next generation of Glytactin with 40% less Phe per gram of PE than all other GMP-based PKU medical foods.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the phenylketonuria treatment market in its latest study, presenting historical demand assessment of 2015 – 2019 and projections for 2020 – 2030. The research study is based on PKU ingredients (protein ingredient [Glycomacropeptide (GMP) and essential and non-essential amino acids] and finish products [Glycomacropeptide (GMP) and essential and non-essential amino acids]), targeted customer (protein ingredients [consumer healthcare companies, pharmaceutical companies, and contract manufacturing companies (CMOs)] and finish products [adults, paediatrics, and pregnant women]), form (protein ingredients [powder blend and granules], finish products [powder & granules, tablets, capsules, powder sachets, ready-to-drink, shakes, and other]), and sales channel (protein ingredients [industry sales], finish products [hospital pharmacies, retail pharmacies, online pharmacies, and hypermarkets & supermarkets]), across seven key regions of the world.

Browse Research Release at: https://www.persistencemarketresearch.com/market-research/phenylketonuria-treatment-market.asp

Browse End-to-end Market: Healthcare

Related Reports:

Contrast Media Injection Sets Market:

https://www.persistencemarketresearch.com/market-research/contrast-media-injection-sets-market.asp 

Bipolar Coagulator Market:

https://www.persistencemarketresearch.com/market-research/bipolar-coagulator-market.asp   

About Persistence Market Research 

Overview:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At Persistence Market Research, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact

Rajendra Singh 
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Visit Our Website: https://www.persistencemarketresearch.com 

Content Source: 

https://www.persistencemarketresearch.com/mediarelease/phenylketonuria-treatment-market.asp  

Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.